Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioTime (now known as Lineage Cell Therapeutics) is a biotechnology company that historically focused on the development of synthetic solutions for surgery, plasma volume replacement, and emergency care. Its lead commercial product, Hextend, is a physiologically balanced blood plasma volume expander used to treat hypovolemia during major surgery and trauma. The company also developed PentaLyte and HetaCool, which are designed for short-term volume expansion and blood replacement during hypothermic surgery, respectively. While the company has since pivoted toward cell therapy and regenerative medicine, its surgical product line remains a significant part of its historical portfolio and clinical development legacy.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Products for Surgery.